Hepatic veno-occlusive disease

Hepatic veno-occlusive disease
Synonyms	Sinusoidal obstruction syndrome
Pronounce	N/A
Specialty	N/A
Symptoms	Jaundice, hepatomegaly, ascites, weight gain
Complications	Liver failure, multi-organ failure
Onset	Typically within 3 weeks of hematopoietic stem cell transplantation
Duration	Varies, can be acute or chronic
Types	N/A
Causes	Chemotherapy, radiation therapy, pyrrolizidine alkaloids
Risks	Bone marrow transplantation, liver transplantation, certain chemotherapy regimens
Diagnosis	Clinical diagnosis, Doppler ultrasound, liver biopsy
Differential diagnosis	Budd-Chiari syndrome, congestive heart failure, acute liver failure
Prevention	N/A
Treatment	Supportive care, defibrotide
Medication	N/A
Prognosis	Variable, depends on severity and response to treatment
Frequency	Rare, but more common in patients undergoing stem cell transplantation
Deaths	N/A

Other Names: Hepatic veno-occlusive disease; Sinusoidal obstruction syndrome Hepatic veno-occlusive disease (hepatic VOD) is a condition resulting from toxic injury to the hepatic sinusoidal capillaries that leads to obstruction of the small hepatic veins

Epidemiology

Prevalence is unknown but hepatic VOD is a rare disease. Endemic zones have been identified in which the disease is associated with the consumption of herbal tea containing pyrrolizidine alkaloids. Epidemics affecting several hundred individuals may occur after contamination of the harvest with these plants.

Cause

Hepatic sinusoidal endothelial cell lesions appear to be the primary cause of the disease, leading to non-thrombotic occlusion of hepatic veins with concentric subendothelial thickening associated with edema and eventually fibrosis.

Signs and symptoms

It affects children and adults. The clinical picture is characterized by painful hepatomegaly, jaundice, and fluid retention that manifests by weight gain, edemas, and ascites. Hepatic insufficiency manifesting as coagulopathy and hepatic encephalopathy may occur. Functional renal insufficiency is common. In severe cases, multiple organ failure or severe bacterial infections may occur. In developed countries, hepatic veno-occlusive disease is mainly associated with the conditioning regimen for hematopoietic stem cell transplantation, with 10 to 60% of transplant patients (depending on the conditioning regimen protocol used) developing hepatic VOD. Hepatic VOD may also occur after chemotherapy or radiation therapy. For most diseases, symptoms will vary from person to person. People with the same disease may not have all the symptoms listed. 80%-99% of people have these symptoms

• Abdominal pain(Pain in stomach)
• Ascites(Accumulation of fluid in the abdomen)
• Elevated hepatic transaminase(High liver enzymes)
• Hepatomegaly(Enlarged liver)
• Increased body weight
• Increased total bilirubin(High bili total)
• Jaundice(Yellow skin)
• Renal insufficiency(Renal failure)
• Respiratory failure

30%-79% of people have these symptoms

• Prolonged partial thromboplastin time

1%-4% of people have these symptoms

• Hepatic encephalopathy

Diagnosis

Diagnosis is based on recognition of the clinical manifestations (hepatomegaly, jaundice, and weight gain) and their association with a potential cause of hepatic VOD (hematopoietic stem cell transplantation or chemotherapy, exposure to pyrrolizidine alkaloids), together with exclusion of other causes of liver disease. Liver biopsy is often indicated. Imaging studies, particularly hepatic Doppler-ultrasonography, may help to confirm the diagnosis. Differential diagnosis Differential diagnoses include other causes of acute or chronic liver disease, and, in the case of hematopoietic stem cell transplantation, graft-versus-host disease and severe infections.

Treatment

No specific treatment is available. Defibrotide is frequently used, mainly on the basis of limited studies (historic comparisons) and because side effects are uncommon. Preventive treatment with heparin is often indicated, but its efficacy has not been proven. In case of hematopoietic stem cell transplantation, the main prophylactic treatment is the use of less hepatotoxic conditioning regimens.

Prognosis

Severity and course of the disease vary between patients. In severe cases, the prognosis is poor with a high mortality rate (up to 90%) due to multiple organ failure.

NIH genetic and rare disease info

• NIH info on Hepatic veno-occlusive disease

Hepatic veno-occlusive disease is a rare disease.

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia